Evidence map›Paper›PMID 40827505›Full record

ArticleJournal of neurochemistry2025

Cerebral Dopamine Neurotrophic Factor (CDNF) Acts as a Trophic Factor Promoting Neuritogenesis in the Dorsal Root Ganglia (DRG) Neurons Through Activation of the PI3K Signaling Pathway.

Raphael de Siqueira Santos, Flávia Natale Borba, Dahienne Ferreira de Oliveira, Marcelo Felippe Santiago, Alexandre Martins do Nascimento, Deborah Schechtman, Debora Foguel

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raphael de Siqueira SantosInstituto de Bioquímica Médica Leopoldo De Meis, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0001-8942-0850
Flávia Natale BorbaInstituto de Bioquímica Médica Leopoldo De Meis, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0009-0006-3771-0390
Dahienne Ferreira de OliveiraInstituto de Bioquímica Médica Leopoldo De Meis, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-8104-9476
Marcelo Felippe SantiagoInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0003-2428-9606
Alexandre Martins do NascimentoDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-1809-0732
Deborah SchechtmanDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-8874-7023
Debora FoguelInstituto de Bioquímica Médica Leopoldo De Meis, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0001-7312-7115

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de JaneiroFundação de Amparo à Pesquisa do Estado de São Paulo
6 · The paper itself

Abstract

The cerebral dopamine neurotrophic factor (CDNF) is a neurotrophic factor extensively studied in the central nervous system because of its neuroprotective effects; however, its role in the peripheral nervous system (PNS) remains less explored. In this study, we used primary dorsal root ganglia (DRG) explants to investigate the neuritogenic potential of exogenous CDNF, as well as its neuroprotective activity under trophic factor deprivation. Our findings demonstrate that CDNF-mediated neuroprotection remains unaffected by the addition of a Trk (tropomyosin receptor kinase) inhibitor or anti-nerve growth factor (NGF) antibody, indicating that CDNF's neurotrophic activity is independent of TrkA signaling. Furthermore, CDNF binding to KDEL-receptor (KDEL-R) was essential for its protective effect, as the CDNF variant lacking the KDEL-R binding sequence (CDNF-ΔKTEL) displayed no significant neuroprotection. Additionally, the simultaneous administration of NGF and CDNF to DRG explants resulted in an additive enhancement of their trophic activities. Notably, both CDNF- and NGF-induced neurotrophic effects were PI3K-dependent, reinforcing the role of this signaling pathway in their mechanisms of action. Taken together, our findings highlight CDNF's crucial role in the PNS, ensuring that NGF-independent neurogenesis can occur. This suggests that CDNF could be further explored in conditions where NGF levels are low or where NGF signaling inhibition is desirable, such as in chronic pain management.

Indexed as

Ganglia, SpinalNerve Growth FactorsNeuritesNeurogenesisNeuronsPhosphatidylinositol 3-KinasesSignal TransductionAnimalsCells, CulturedNerve Growth FactorRatsRats, Sprague-DawleyNerve Growth FactorNerve Growth FactorsPhosphatidylinositol 3-Kinasescerebral dopamine neurotrophic factordorsal root gangliaKDEL‐receptornerve growth factorPI3K/AKT

Identifiers

PMID40827505
PMCPMC12362333

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.